Joey Frenette

Joey Frenette

InvestorPlace Contributor

Joey Frenette, an esteemed investment writer since 2016, has cultivated expertise in the realms of tech and consumer stocks. His analyses, as featured in publications such as The Motley Fool Canada, TipRanks, and Barchart, exemplify a commitment to the principles of value investing, drawing inspiration from the great Warren Buffett.

Joey’s narrative is enriched by his experience working as a software engineer (he obtained his B.A.Sc in Computer Engineering from the University of British Columbia), a role that imbued a strong understanding of the dynamics of the disruptive technology scene. His financial skill set is underscored by his passing the CFA Level 1 exam on the first attempt.

Joey’s strategic approach brings together the worlds of value and growth investing. By integrating tech-driven insights with his financial compass, Joey strives to find relative value where others may not.

Recent Articles

3 Impressive AI Stocks That Cathie Wood Is Betting On Now

By Joey Frenette, InvestorPlace Contributor

Cathie Wood has been loading up on shares of some pretty interesting AI stocks in recent quarters, some of which may still be cheap.

Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone

By Joey Frenette, InvestorPlace Contributor

The trillion-dollar market cap club could fill with some high-momentum large-caps that could give the Magnificent Seven a good run.

3 Leading AI Stocks That May Actually Be Value Plays

By Joey Frenette, InvestorPlace Contributor

The leading AI value stocks aren't as expensive as you'd think, especially given their ability to transform expenditures into future growth.

3 Chip Stocks to Buy for the AI Tsunami

By Joey Frenette, InvestorPlace Contributor

The AI tsunami could continue going into year's end, helping pave the way for these chip stocks to buy for AI.

Harnessing AI for Drug Discovery: Top 3 Stocks to Watch

By Joey Frenette, InvestorPlace Contributor

As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly.

Load More